Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-118 in advanced malignancies
NCT05025358Phase 1Completed
- Sponsor
- Lupeng Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LP-118 in solid tumor and lymphoma, sponsored by Lupeng Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 24 months, Adverse Events at 24 months and 4 more. Started Sep 2021; status: completed.
02
Drugs
LP-118
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05025358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025358.